SCHEMBL7705076

SCHEMBL7705076

CC1Oc2ccc(CCN(Cc3cccc(Cl)c3)C(=O)OC(C)(C)C)cc2NC1=S

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.35
RIPK1 Q13546 1/20 0.34
PARP1 P09874 1/20 0.34
SLC2A1 P11166 1/20 0.34
LPAR1 Q92633 1/20 0.34
LPAR5 Q9H1C0 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HTR2B P41595 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
ALDH1A1 P00352 1/20 0.32
TSHR P16473 1/20 0.32
MBTPS1 Q14703 1/20 0.32
GHSR Q92847 2/20 0.32
HDAC3 O15379 2/20 0.32
HDAC2 Q92769 2/20 0.32
NCOR2 Q9Y618 2/20 0.32
AOC3 Q16853 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7708255 0.94 RIPK1 (0.36) HDAC1RIPK1PARP1SLC2A1SMN1; SMN2
SCHEMBL6428132 0.93 RIPK1 (0.36) HDAC1RIPK1PARP1SLC2A1SMN1; SMN2
SCHEMBL7708154 0.91 PARP1 (0.44) HDAC1RIPK1PARP1SLC2A1LPAR1
SCHEMBL6302929 0.85 PARP1 (0.35) HDAC1PARP1ALDH1A1TSHRHDAC3
SCHEMBL6309909 0.85 HSD17B10 (0.33) HDAC1PARP1SMN1; SMN2ALDH1A1TSHR
SCHEMBL6309617 0.85 HDAC1 (0.43) HDAC1PARP1SMN1; SMN2ALDH1A1HDAC3
SCHEMBL7704945 0.85 HDAC3 (0.44) HDAC1PARP1SMN1; SMN2ALDH1A1HDAC3
SCHEMBL7711139 0.84 PARP1 (0.48) HDAC1RIPK1PARP1SMN1; SMN2ALDH1A1
SCHEMBL6302723 0.84 PARP1 (0.47) HDAC1RIPK1PARP1SMN1; SMN2ALDH1A1
SCHEMBL7712797 0.84 RIPK1 (0.36) HDAC1RIPK1PARP1LPAR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed